Growth Hormone Peptide Fights Muscle Wasting in Severe Duchenne Muscular Dystrophy Mice

Four-week-old D2-mdx mice (a severe DMD model with hyper-fibrotic and atrophic phenotype) received subcutaneous JMV2894 at 640 or 1280 µg/kg for six weeks. Researchers measured hind limb muscle function (plantar flexor torque), muscle volume (ultrasound), echo-density, muscle fiber size (histology), fibrosis, gene expression of matrix-remodeling and atrophy markers, and IGF-1 levels in plasma and tissue.

Duchenne muscular dystrophy is a devastating genetic disease with no cure, causing progressive muscle wasting and early death. This study provides the first evidence that a growth hormone secretagogue peptide can combat muscle atrophy in a severe DMD mouse model through IGF-1 signaling. The anti-atrophic, anti-inflammatory, and anti-fibrotic properties of JMV2894 suggest growth hormone secretagogues could be a multi-target therapeutic approach for DMD.

DMD treatment has historically focused on corticosteroids and gene therapy approaches. Growth hormone secretagogues offer a completely different angle — combating muscle atrophy through the GH/IGF-1 axis while also reducing inflammation and fibrosis. If the formulation can be improved for better muscle exposure, GHS peptides could become a supportive therapy alongside emerging gene-based treatments for DMD.

This is a preclinical mouse study — results may not translate to human DMD patients. The D2-mdx model, while severe, doesn't fully replicate human disease. The anti-fibrotic effect was mild despite gene expression changes, and limited drug exposure to muscle tissue suggests formulation improvements are needed. The lower dose was surprisingly more effective for some outcomes, which is not fully explained.